Leica Biosystems Expands Its Clinical Digital Pathology Portfolio with New Launches at DPAI 2025
Leica Biosystems, a Danaher company and a world leader in anatomic pathology solutions, is accelerating the digital transformation of pathology by unveiling three new offerings at the Digital Pathology and AI (DPAI) Congress in London. The Aperio GT 180 DX scanner, the Aperio CS5 DX scanner, and the Aperio iQC DX software join Leica’s Aperio Digital Pathology portfolio, making their European debut at booth #5.
Aperio iQC DX marks a major advancement in digital pathology quality control. This software standardizes QC workflows, reducing variability and ensuring consistent results across laboratories. By automatically detecting artifacts and cutting down on manual review time, iQC DX helps lab teams operate more efficiently while upholding top-tier clinical standards.
Following the renowned Aperio GT 450 DX scanner, the Aperio GT 180 DX delivers superb image quality and fast performance tailored for mid-volume laboratories. In addition, the Aperio CS5 DX scanner can scan 1x3 inch and 2x3 inch slides and offers output in DICOM or SVS formats. Together, these new devices give pathology labs a choice of scanners that fit their scale and needs, all backed by the proven trust of Aperio-quality performance.
Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems, commented: the introduction of the Aperio GT 180 DX, Aperio CS5 DX, and Aperio iQC DX reinforces Leica’s commitment to delivering rapid, effective clinical solutions that broaden the Aperio Digital Pathology suite to meet diverse departmental requirements. He added that advancing innovative solutions at a pace that aligns with clinical demands is central to Leica’s mission, driven by the urgent need for faster, more accurate diagnostics and a focus on empowering pathologists to improve patient outcomes.
In addition to the new offerings, Leica highlights a broader ecosystem: Aperio HALO AP, Aperio GT 450 DX, Aperio GT 180 DX, Aperio CS5 DX, and Aperio iQC DX, all CE-marked under IVDR for in-vitro diagnostic use. Other products are designated for research use only, and availability may vary by country. Notably, Aperio HALO AP and HALO Link software are developed in collaboration with Indica Labs and are sold exclusively through Leica Biosystems.
About Leica Biosystems
Leica Biosystems is a global cancer diagnostics company specializing in both anatomical and digital pathology solutions. Its end-to-end product portfolio covers every step of the pathology workflow—from specimen preparation and staining to imaging and reporting. As the only company owning the full process from biopsy to diagnosis, Leica Biosystems is uniquely positioned to streamline transitions between stages. The company’s mission, “Advancing Cancer Diagnostics, Improving Lives,” guides its culture. Leica Biosystems operates as a subsidiary of Danaher Corporation.
Contact: Matt McCutcheon, Senior Manager, Global External Communications, Leica Biosystems
